Cas: 100-54-9 was involved in experiment | Crystal Growth & Design 2022

3-Cyanopyridine(cas: 100-54-9) has been shown to have a number of pharmacological effects: it inhibits the production of prostaglandin E2 and nitric oxide in congestive heart failure patients; it prevents the formation of diazonium salt from benzene and nitrogen dioxide; it inhibits the growth of tumor cell lines; and it protects mice from radiation injury by scavenging reactive oxygen species. COA of Formula: C6H4N2

Efe, Sevval;Schauerte, Carsten;Merz, Klaus published 《Crystal Engineering under Hydrothermal Conditions: Cocrystals and Reactions of 3-Cyanopyridine with Glutaric Acid》 in 2022. The article was appeared in 《Crystal Growth & Design》. They have made some progress in their research.COA of Formula: C6H4N2 The article mentions the following:

Crystallization under hydrothermal conditions is an interesting method to selectively influence crystallization pathways and processes. Crystallization of 3-cyanopyridine and glutaric acid from aqueous solutions under ambient conditions leads to the 2:1 cocryst. entity 1 of 3-cyanopyridine and glutaric acid. Crystallizations under thermal and hydrothermal conditions lead, depending on the amounts of water used, to both the polymorphic forms 1 and 2 of the 2:1 cocryst. entity of 3-cyanopyridine and glutaric acid and furthermore to the cocryst. entity nicotinamide and glutaric acid. To complete the study, the researchers used 3-Cyanopyridine (cas: 100-54-9) .

3-Cyanopyridine(cas: 100-54-9) has been shown to have a number of pharmacological effects: it inhibits the production of prostaglandin E2 and nitric oxide in congestive heart failure patients; it prevents the formation of diazonium salt from benzene and nitrogen dioxide; it inhibits the growth of tumor cell lines; and it protects mice from radiation injury by scavenging reactive oxygen species. COA of Formula: C6H4N2

Reference:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem